COVID-19 Teleneuropsychology (TeleNP) Webinar

Educational Objectives

  1. Describe the evidence base supporting TeleNP procedures.
  2. List the strengths and limitations of different TeleNP models.
  3. Apply their knowledge of TeleNP models to clinical and research practice.
  4. Analyze the potential feasibility of TeleNP procedures within their own professional settings.
  5. Assess key legal and ethical considerations when providing TeleNP services.

The International Neuropsychological Society is approved by the American Psychological Association to sponsor continuing education for psychologists. The International Neuropsychological Society maintains responsibility for this program and its content.

Course Information

Target Audience:Intermediate
Availability:

Date Available: 2020-04-14

You may obtain CE for this webinar at any time.

Offered for CEYes
Cost

Members $40

Non-Members $60

Refund PolicyThis webinar is not eligible for refunds
CE Credits2.0

Abstract

In response to the Coronavirus (COVID-19) outbreak, there is a pressing need for neuropsychology to apply tele-communication technologies to deliver services to patients unable to attend in-person appointments. Encouragingly, new evidence is emerging to support development of novel models of neuropsychology service delivery remotely. Using North America and Australia as examples, this webinar will illustrate the many opportunities and challenges of Teleneuropsychology(TeleNP) assessment, including focusing on ethical/legal issues during service provision as well as addressing practical needs for providers attempting service delivery remotely.

Disclosures

None

Author(s)

Munro Cullum, PhD is a Clinical Neuropsychologist who specializes in the assessment of cognitive disorders. He is board-certified in Clinical Neuropsychology (ABPP/ABCN) and serves as the Vice Chair and Chief of the Division of Psychology in the Department of Psychiatry, where he holds the Pamela Blumenthal Distinguished Professorship in Clinical Psychology. He is the PI of the Concussion-Texas (ConTex) studies, serves as the Scientific Director of the Texas Alzheimer’s Research and Care Consortium (TARCC) and is co-leader of Clinical Core Leader in the UTSW Alzheimer’s Disease Center. He is a past-president of the Society for Clinical Neuropsychology and the National Academy of Neuropsychology and the incoming President of the Sports Neuropsychology Society. He is actively involved in research, teaching, and clinical practice in neuropsychology. His research includes investigations into short and long term effects of concussion and early detection and differential diagnosis of neurodegenerative conditions of aging. His clinical research lab is also involved in cognitive test development and in telemedicine applications of neuropsychology.

Lana Harder, PhD leads the Neuropsychology Service and Neuropsychology training program at Children’s Health in Dallas, Texas. She holds dual faculty appointments as Associate Professor of Psychiatry and Neurology at UT Southwestern. She is board certified in Clinical Neuropsychology and is a board-certified Subspecialist in Pediatric Neuropsychology. Nationally, Dr. Harder serves on the Board of Directors of the American Board of Clinical Neuropsychology (ABCN) and the Association of Postdoctoral Programs in Clinical Neuropsychology (APPCN) and serves on the Board of Directors and Medical and Scientific Council of the Seigel Rare Neuroimmune Association. She is a Fellow of the National Academy of Neuropsychology. Dr. Harder earned her doctorate from the University of Texas at Austin and completed her pre-doctoral internship at the Kennedy Krieger Institute and Johns Hopkins School of Medicine. She completed post-doctoral fellowship at Texas Children’s Hospital and Baylor College of Medicine. Dr. Harder has served as a Pediatric Neuropsychologist at Children’s Health since 2008. She was a founding member and is the current Co-Director of the Children’s Pediatric Demyelinating Diseases Clinic. Dr. Harder published the first paper on pediatric tele-neuropsychological assessment. In addition to this work, her research interests include brain imaging correlates of neuropsychological functioning in transverse myelitis and multiple sclerosis and longitudinal cognitive and psychosocial outcomes for pediatric multiple sclerosis, transverse myelitis, acute disseminated encephalomyelitis, and neuromyelitis optica.

Rene Stolwyk, PhD is a senior lecturer and clinical neuropsychologist, based at the Turner Institute for Brain and Mental Health at Monash University in Melbourne, Australia. A passionate scientist-practitioner, Dr. Stolwyk enjoys working at the nexus of research, clinical practice and clinical education. He has extensive clinical experience working in stroke rehabilitation, including at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He is the founder and clinical lead of the Monash TeleNeuropsychology Service, a world first initiative using digital health technology to open up much needed neuropsychological assessment and rehabilitation services to rural neurology patients throughout Australia. Dr. Stolwyk is convenor of the Clinical PhD in Clinical Neuropsychology training program at Monash University. He leads a team of highly-skilled educators providing excellence in clinical training to the next generation of Australian neuropsychologists. From a research perspective, Dr. Stolwyk leads the stroke and telehealth research theme within the Monash-Epworth Rehabilitation Research Centre. He supervises a team of 12 research fellows, research officers and doctoral students and has published over 50 scientific works aimed at improving outcomes for survivors of brain injury.

Dustin B. Hammers, PhD is an Associate Professor in the Department’s Division of Cognitive Neurology at University of Utah. His career special interests include assessing cognition in patients across the lifespan, related to concerns ranging from adult ADHD to Alzheimer’s disease. His research has focused on relationships between brain imaging and neuropsychological test performance, detection of early cognitive decline in the elderly through novel measures, and – more recently – assessment of cognitive change over time.